Evidence map›Paper›PMID 31152393›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2019

Optimization of Metabolic Labeling with Alkyne-Containing Isoprenoid Probes.

Mina Ahmadi, Kiall Francis Suazo, Mark D Distefano

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. ACS chemical biology · 2022
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Mina AhmadiDepartment of Chemistry, University of Minnesota, Minneapolis, MN, USA.
Kiall Francis SuazoDepartment of Chemistry, University of Minnesota, Minneapolis, MN, USA.
Mark D DistefanoDepartment of Chemistry, University of Minnesota, Minneapolis, MN, USA. diste001@umn.edu.
University of Minnesota · US

Funding

Enzymatic Protein LabelingR01GM084152 · NIGMS · UNIVERSITY OF MINNESOTA · PI DISTEFANO, MARK D · 2010 to 2019
$2.6M
Dysregulation of Protein Prenylation in the Pathogenesis of Alzheimer's DiseaseRF1AG056976 · NIA · UNIVERSITY OF MINNESOTA · PI DISTEFANO, MARK D, LI, LING · 2017 to 2017
$1.9M
NIA NIH HHS RF1 AG056976NIGMS NIH HHS R01 GM084152
6 · The paper itself

Abstract

Protein prenylation, found in eukaryotes, is a posttranslational modification in which one or two isoprenoid groups are added to the C terminus of selected proteins using either a farnesyl group or a geranylgeranyl group. Prenylation facilitates protein localization mainly to the plasma membrane where the prenylated proteins, including small GTPases, mediate signal transduction pathways. Changes in the level of prenylated proteins may serve a critical function in a variety of diseases. Metabolic labeling using modified isoprenoid probes followed by enrichment and proteomic analysis allows the identities and levels of prenylated proteins to be investigated. In this protocol, we illustrate how the conditions for metabolic labeling are optimized to maximize probe incorporation in HeLa cells through a combination of in-gel fluorescence and densitometric analysis.

Indexed as

Protein PrenylationHeLa CellsHumansProteomicsStaining and LabelingTerpenesTerpenesFarnesylationGeranylgeranylationIn-gel fluorescenceIsoprenoid analogLovastatinMetabolic labelingProtein prenylation

Identifiers

PMID31152393
PMCPMC6690435
OpenAlexW2947114801

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.